Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 7/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237367 | 0.87 | LOXL2 (0.45) | LOXL2MAOA | |
| SCHEMBL5239013 | 0.83 | LOXL2 (0.47) | LOXL2MAOACYP1A1CYP1A2CTSV | |
| SCHEMBL5346660 | 0.73 | MAOA (0.72) | MAOACYP1A1CYP1A2KDM4EALDH1A1 | |
| SCHEMBL5279447 | 0.72 | MAOA (0.48) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL11389530 | 0.70 | MAOA (0.72) | LOXL2MAOACYP1A2KDM4EALDH1A1 | |
| SCHEMBL5349187 | 0.69 | MAOA (0.76) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL14443979 | 0.68 | NUDT1 (0.53) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL14443973 | 0.68 | IKBKB (0.58) | MAOACTSVKDM4E | |
| SCHEMBL6285040 | 0.67 | MAOA (0.72) | MAOAKDM4EALDH1A1NPC1LMNA | |
| SCHEMBL12205565 | 0.66 | MAOA (0.65) | MAOAKDM4EALDH1A1NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933396-B2 | Process to prepare psorospermin | CYLENE PHARMACEUTICALS (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040102515-A1 | Process to prepare psorospermin | CYLENE PHARMACEUTICALS | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102515-A1 | Process to prepare psorospermin | BPGM, DHPS, FDPS | LOXL2 3973/4885MAOA 761/4885CYP1A1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.